Skip to content

Effect of Masoor Ksheerpista Lepa in Melasma

A CLINICAL STUDY OF MASOOR KSHEERPISTA LEPA IN THE MANAGEMENT OF VYANGA - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068454
Enrollment
40
Registered
2024-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma Health Condition 2: L819- Disorder of pigmentation, unspecified

Interventions

None listed

Sponsors

Shri Narayan Prasad Awasthi Government Ayurved College Raipur Chhattisgarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with classical symptom of Vyanga Mukhamagatya Mandal, nirujam, tanukam syav Suspicious patients with symptoms of diseases described in modern texts.

Exclusion criteria

Exclusion criteria: Those whose age is less than 18 years and more than 60 years. In case of repeated occurrence of Urticaria. Infectious diseases like eg-herpes, fungal infection. In case of any kind of allergy in the skin. skin cancer patients. Accidental injury in mark. Birth marks. With present and past history of any skin disease e.g.Psoriasis,Vitiligo,Dermititis. Any history of hypersensitivity to creams or lotions,lepa. Any skin disease like fungal infection ,viral infection. Person with endocrinal disorder like cushing’s or addisions disease, acne.

Design outcomes

Primary

MeasureTime frame
1.Colour of skin 2.Size of affected area 3.Texture of affected area (oily/Dry) Timepoint: 15 days

Secondary

MeasureTime frame
Reduction in the color of patch reduction in the size Timepoint: 15days,30days,45days,60days

Countries

India

Contacts

Public ContactDr Sasmita Tripathy

Shri Narayan Prasad Awasthi Government Ayurved College Raipur Chhattisgarh

ansharma260@gmail.com9827115211

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026